NGM Biopharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

NGM Biopharmaceuticals

07/05/2021 19:35

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 36 cents​​ per share for the quarter ended
in March. The mean expectation of eight analysts for the quarter
was for a loss of 42 cents per share.
* Revenue fell 11.4% to $21.58 million from a year ago​; 
analysts expected $22.49 million.
* NGM Biopharmaceuticals Inc's reported EPS for the quarter was
a loss of 36 cents​.
* The mean earnings estimate of analysts had risen by
about 10.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* NGM Biopharmaceuticals Inc shares had fallen by 8.0% this
quarter and lost 11.7% so far this year.
* The company reported a quarterly loss of $27.54 million.
* Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $40.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 7 at 06:35 p.m. GMT. ​All
figures in US Dollars.​